Conference call with members from Executive Management on outcome of semaglutide Advisory Committee meeting
On 19 October 2017 at 08.00 am CEST, corresponding to 2.00 am EST, a conference call for investors will be held.
Please use the below link to access the webcast and presentation.
- Conference call presentation
If you have any
questions, you are welcome to contact Novo Nordisk Investor Relations:
+45 3075 9085 Peter Hugreffe
Ankersen
+45 3079 8519 Hanna Ögren
+45
3079 4461 Anders Mikkelsen
+45 3079
3009 Christina Kjær
+1 609 235 8567
Kasper Veje
